Effect of standardized Aronia Melanocarpa extract on oxidative stress and antioxidant status in patient with chronic myeloid leukemia treated with imatinib
-
Published:2024-04
Issue:02
Volume:69
Page:9-17
-
ISSN:1857-8969
-
Container-title:Macedonian Pharmaceutical Bulletin
-
language:en
-
Short-container-title:Maced. Pharm. Bull.
Author:
Labachevski Bojan1, Zendelovska Dragica1, Petrushevska Marija1, Popova-Labachevska Marija2, Pivkova-Veljanovska Aleksandra2, Gjatovska-Labachevska Liljana3, Ridova Nevenka2, Trajkova Sanja2, Panovska-Stavridis Irina2, Balkanov Trajan1
Affiliation:
1. Institute of Preclinical and Clinical Pharmacology and Toxicology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 50 Divizija 6, 1000 Skopje, RN Macedonia 2. University clinic of hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 50 Divizija 6, 1000 Skopje, RN Macedonia 3. Institute for Microbiology and Parasitology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 50 Divizija 6, 1000 Skopje, RN Macedonia
Abstract
Antioxidant status in patients with chronic myeloid leukemia (CML) is significantly decreased in comparison with healthy individuals. Oxidative stress (OS) may be associated with the pathophysiology of CML and can influence on development of resistance to imatinib.
The aim of our study was to investigate the effect of Aronia melanocarpa extract (A-lixir 400 PROTECT®) on OS in CML patients treated with imatinib.
In this study a total of 40 CML patients treated with imatinib for longer than 1 month were included: twenty patients were treated with imatinib and A-Lixir 400 PROTECT® (treatment group) and twenty patients were treated only with imatinib (control group). OS parameters (d-ROM, PAT and OSI) were measured at the initial visit, and after 21 and 42 days of treatment. Adjuvant treatment with A-Lixir 400 PROTECT® could lead to attenuation of OS. d-ROM and OSI in this group of patients were significantly higher at initial visit when compared to values after 21 and 42 days of treatment (p<0.05). Total antioxidant capacity (PAT) was significantly higher after 21 and 42 days of treatment initiation in comparison with the pretreatment values. In the control group no significant differences were obtained between investigated parameters at any time of measurement. We can conclude that adjuvant treatment with A-Lixir 400 PROTECT® after 21 and 42 days lead to significant reduction of OS in patients with CML treated with imatinib.
Keywords: Oxidative stress, d-ROM, PAT, OSI, chronic myeloid leukemia, imatinib, Aronia melanocarpa
Publisher
Macedonian Pharmaceutical Association
Reference30 articles.
1. Ahmad, R., Tripathi, A.K., Tripathi, P., Singh, R., Singh, S., Singh, R.K., 2010. Studies on lipid peroxidation and non-enzymatic antioxidant status as indices of oxidative stress in patients with chronic myeloid leukaemia. Singapore Med. J. 51(2), 110–115. 2. Ahmad, R., Tripathi, K.A., Tripathi, P., Singh, R., Singh, S., Singh K.R., 2008. Oxidative stress and antioxidant status in patients with chronic myeloid leukemia. Indian Journal of Clinical Biochemistry 23(4), 328-333, 3. Alberti, A., Bolognini, L., Macciantelli, D., Caratelli, M., 2000. The radical cation of N,N-diethyl-paraphenylendiamine: A possible indicator of oxidative stress in biological samples. Res. Chem. Interm. 26, 253–67. 4. Ammar, M., Mahmoud, L.B., Medhaffar, M., Ghozzi, H., Sahnoun, Z., Hakim, A., Mseddi, M., Elloumi, M., Zeghai, K., 2020. Relationship of oxidative stress in the resistance to imatinib in Tunisian patients with chronic myeloid leukaemia: A retrospective study. J. Clin. Lab. Anal. 34, e23050. https//doi.org/10.1002/jcla.23050 5. Burton-Freeman, B., 2019. A Selective Role of Dietary Anthocyanins and Flavan-3-ols in Reducing the Risk of Type 2 Diabetes Mellitus: A Review of Recent Evidence. Nutrients 11(4), 841. https://doi.org/10.3390/nu11040841
|
|